Literature DB >> 9878784

Neurotransmitters, KCl and antioxidants rescue striatal neurons from apoptotic cell death in culture.

L Iacovitti1, N D Stull, A Mishizen.   

Abstract

Striatal neurons grown in low density culture on serum-free media and in the absence of glia die within 3 days of plating. In this study, we sought to determine the mechanism of cell death (e.g., apoptosis) and whether trophic influences, such as, growth factors, neurotransmitters, antioxidants or KCl-mediated depolarization could improve their survival. We found that striatal neurons grown in this manner die via apoptosis unless treated with one of several different rescuing agents. One way to prevent the death of most striatal neurons was continual treatment with 5-20 microM dopamine (DA) or other monoamines. Although the survival effect of DA was mimicked by the specific D1 receptor agonist, SKF38393, no D1 or D2 receptor antagonists blocked the effect. As with DA, chronic depolarization with KCl (12-39 mM) or treatment with antioxidants, such as the vitamin E analog, Trolox (10-10-500 microM), or the hormone, melatonin (10-10-500 microM) also rescued striatal neurons from impending cell death. Surprisingly, growth factors, such as BDNF, bFGF, GDNF, NGF, NT3 and EGF, demonstrated no ability to rescue striatal neurons in this model, suggesting that death was not solely caused by the absence of essential trophic factors. We conclude that a variety of agents, but not growth factors, can prevent the demise of striatal neurons, presumably by neutralizing damage at one or more steps in the death cascade. Copyright 1999 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9878784     DOI: 10.1016/s0006-8993(98)00955-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  15 in total

1.  Dopamine promotes the survival of embryonic striatal cells: involvement of superoxide and endogenous NADPH oxidase.

Authors:  Liping Ma; Jiawei Zhou
Journal:  Neurochem Res       Date:  2006-05-09       Impact factor: 3.996

2.  Latent stem and progenitor cells in the hippocampus are activated by neural excitation.

Authors:  Tara L Walker; Amanda White; Debra M Black; Robyn H Wallace; Pankaj Sah; Perry F Bartlett
Journal:  J Neurosci       Date:  2008-05-14       Impact factor: 6.167

Review 3.  Melatonin and Parkinson's disease.

Authors:  Juan C Mayo; Rosa M Sainz; Dun-Xian Tan; Isaac Antolín; Carmen Rodríguez; Russel J Reiter
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

Review 4.  Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease?

Authors:  A Barzilai; E Melamed; A Shirvan
Journal:  Cell Mol Neurobiol       Date:  2001-06       Impact factor: 5.046

5.  Studies on the differentiation of dopaminergic traits in human neural progenitor cells in vitro and in vivo.

Authors:  Ming Yang; Angela E Donaldson; Cheryl E Marshall; James Shen; Lorraine Iacovitti
Journal:  Cell Transplant       Date:  2004       Impact factor: 4.064

6.  Expression of the striatal DARPP-32/ARPP-21 phenotype in GABAergic neurons requires neurotrophins in vivo and in vitro.

Authors:  S Ivkovic; M E Ehrlich
Journal:  J Neurosci       Date:  1999-07-01       Impact factor: 6.167

7.  Neurotoxicity of HIV-1 Tat protein: involvement of D1 dopamine receptor.

Authors:  Janelle M Silvers; Marina V Aksenova; Michael Y Aksenov; Charles F Mactutus; Rosemarie M Booze
Journal:  Neurotoxicology       Date:  2007-07-22       Impact factor: 4.294

Review 8.  The antiapoptotic activity of melatonin in neurodegenerative diseases.

Authors:  Xin Wang
Journal:  CNS Neurosci Ther       Date:  2009-10-10       Impact factor: 5.243

Review 9.  Cell-based therapies for Parkinson's disease: past, present, and future.

Authors:  Kathleen M Fitzpatrick; James Raschke; Marina E Emborg
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

10.  First experimental evidence of dopamine interactions with negatively charged model biomembranes.

Authors:  Katarzyna Jodko-Piorecka; Grzegorz Litwinienko
Journal:  ACS Chem Neurosci       Date:  2013-05-10       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.